CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Short Interest Update

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) was the recipient of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 44,900 shares, a drop of 40.6% from the October 31st total of 75,600 shares. Currently, 1.2% of the company’s shares are sold short. Based on an average daily trading volume, of 30,300 shares, the days-to-cover ratio is presently 1.5 days.

Institutional Trading of CASI Pharmaceuticals

An institutional investor recently raised its position in CASI Pharmaceuticals stock. Renaissance Technologies LLC grew its holdings in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) by 10.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 40,800 shares of the biotechnology company’s stock after buying an additional 4,000 shares during the quarter. Renaissance Technologies LLC owned approximately 0.30% of CASI Pharmaceuticals worth $224,000 at the end of the most recent quarter. Institutional investors own 22.23% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on CASI Pharmaceuticals in a research report on Saturday, August 3rd. They set a “hold” rating on the stock.

CASI Pharmaceuticals Trading Down 4.1 %

CASI traded down $0.17 during trading on Thursday, hitting $3.97. 27,749 shares of the stock traded hands, compared to its average volume of 136,349. The firm has a market capitalization of $61.38 million, a P/E ratio of -1.78 and a beta of 0.69. CASI Pharmaceuticals has a 12-month low of $2.05 and a 12-month high of $8.48. The company has a debt-to-equity ratio of 1.38, a current ratio of 3.20 and a quick ratio of 2.32. The firm has a 50-day moving average of $5.61 and a 200 day moving average of $5.45.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.